Publications

Extrapolation from Progression-Free Survival to Overall Survival in Oncology

1 December 2016

This Research Paper reports on a literature review of trials using PFS as a surrogate for OS in oncology between 2012 and 2016; a workshop and…

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

1 December 2016

Published paper using MCDA to obtain preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and to assess the value of obinutuzumab for rituximab-refractory iNHL.

An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’

1 December 2016

This Research Paper explores decisions by the National Institute for Health and Care Excellence (NICE) that new technologies are to be recommended in line with clinical practice (RiLCP). The authors qualitatively assess documentation associated with RiLCP decisions to create a framework to describe common themes, and assess the level of patient access associated with each RiLCP decision.

Uncertainty and Risk in HTA Decision Making

1 November 2016

The quality of decision-making in key public sector bodies dealing with resource allocation is a major determinant of their efficiency. One of the most difficult and contentious areas of decision-making is the way that uncertainty is dealt with.

The Distribution of the EQ-5D-5L Index in Patient Populations

1 October 2016

EQ-5D data are often summarised by an EQ-5D index, whose distribution for its original version, the EQ-5D-3L, often shows two distinct groups in patient populations, arising…

Four Case Studies to Explore the Added Value of Oxford AHSN

9 January 2016

The Oxford Academic Health Science Network (Oxford AHSN) wishes to demonstrate the value of the various projects and programmes that the network has developed and implemented since it was established in 2013.

Improving Efficiency and Resource Allocation in Future Cancer Care

9 January 2016

The economic burden that cancer poses on our society is staggering – 25 million years of healthy life lost, at cost of €126 billion including €52…

How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?

8 January 2016

This report provides a detailed summary of a panel session which took place at the HTAi 2016 annual meeting, Tokyo. The panel session was entitled “How…

“New Age” Decision Making in HTA: Is It Applicable in Asia?

1 August 2016

This report provides a detailed summary of a panel session which took place at the HTAi 2016 annual meeting in Tokyo. The panel session was entitled…